

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/254227 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 31/4545* (2006.01)
C07D 491/107 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/US2024/032683

(22) International Filing Date:
06 June 2024 (06.06.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/506,618 07 June 2023 (07.06.2023) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **CHERNEY, Emily Charlotte**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, PRINCETON, New Jersey 08543 (US). **PURANDARE, Ashok Vinayak**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, PRINCETON, New Jersey 08543 (US). **KUMI, Godwin Kwame**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, PRINCETON, New Jersey 08543 (US). **BALOG, James Aaron**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, PRINCETON, New Jersey 08543 (US).

(74) Agent: **GREENBLATT, Gary D.** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SPIROCYCLIC SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUND



(I)

(57) Abstract: Disclosed is a compound of Formula I: I or stereoisomers, tautomers, or salts thereof. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins; and pharmaceutical compositions comprising the compound. The compound is useful in the treatment of viral infections and proliferative disorders, such as cancer.

WO 2024/254227 A1